###### Significance of this study

What is already known on this subject?
======================================

-   A review of the available literature evaluating the accuracy of narrow band imaging (NBI)--assisted optical diagnosis compared with histological assessment and recommendations from national bodies suggested that optical diagnosis could replace histology for diminutive polyps. Additionally, exploratory work has suggested a short learning curve for NBI-assisted optical diagnosis, making it an attractive option that could be applied widely into clinical practice, if minimal training was required. Notably, the majority of studies were performed by experts in the field of optical diagnosis or in academic centres with limited data from non-expert centres suggesting that the accuracy may not be consistently reproducible in non-expert hands. Confirming whether NBI-assisted optical diagnosis can reproducibly achieve the required level of accuracy is one of the most pressing questions within the field of GI endoscopy. It is essential to establish its accuracy before recommending its use in routine clinical practice.

What are the new findings?
==========================

-   This is the largest multicentre diagnostic study in this field. The study demonstrates that NBI-assisted optical diagnosis cannot currently be recommended for routine use outside of expert centres. The accuracy, both at polyp and patient level, was substantially below recommended levels. Importantly, polyp level analyses identified that accuracy was acceptable when two or more of the features of the NBI International Colorectal Endoscopic (NICE) classification system were positively identified. Possible explanations are that not all polyps exhibit NICE characteristics or that colonoscopists vary in their ability to identify these characteristics.

How might it impact on clinical practice in the foreseeable future?
===================================================================

-   The results of this study confirm that optical diagnosis cannot be recommended for use in routine clinical practice. Further research is required to understand what factors influence the reported variation in the accuracy of NBI-assisted optical diagnosis in this study. This research should focus on polyp and colonoscopist characteristics and training methods.

Introduction {#s2}
============

Colorectal cancer (CRC) is a leading cause of morbidity and mortality in the Western world.[@R1]

Most CRCs develop from adenomas in a well-described adenoma--carcinoma genetic sequence.[@R2] Colonoscopy with polypectomy interrupts this sequence, reducing the rate of subsequent CRC and associated mortality by 40--60%.[@R3] [@R4] Consequently, national bowel cancer screening programmes (BCSPs) have been developed, with over 14 million screening colonoscopies performed annually in the USA alone.[@R5] Improved training, technology and awareness of colonoscopic quality have led to increased polyp detection rates. Over 90% of polyps detected at colonoscopy are small (6--9 mm) or diminutive (≤5 mm), with the latter forming the majority.[@R6] [@R7] Cancer risk or advanced features (villous elements or high-grade dysplasia) particularly in diminutive polyps is low.[@R8] The incidence of dysplastic serrated polyps, thought to be precursors of cancer via an alternative pathway, is lower still, 0.3--0.5%.[@R6] [@R7] [@R9]

Approximately half of small polyps are non-neoplastic with the majority of these being hyperplastic[@R6] [@R7]; therefore, many polypectomies are performed unnecessarily, increasing procedure-related risks such as bleeding and perforation. Currently, even diminutive polyps are resected and examined histologically. The number of adenomas detected is one of the best determinants of long-term risk of advanced neoplasia and informs surveillance decision-making. Diagnosing small polyps by optical diagnosis would allow recto-sigmoid hyperplastic polyps, with no malignant potential, to be diagnosed and left in situ and small adenomas to be resected and discarded without histopathology. Additionally, a positive diagnosis could be made for small polyps not retrieved or unsuitable for histological analysis.[@R10] Optical diagnosis would enable immediate determination of surveillance intervals, with associated time and cost savings.

Traditional white light technology, used at routine colonoscopy, is not accurate enough for optical diagnosis to replace routine histopathological assessment. However, a number of image-enhancing, user-friendly technologies have been developed. NBI (Olympus, Japan) has been the most widely studied. It is a 'blue light' optical imaging modality operated by a button on the colonoscope that, by enhancing mucosal detail and vascular structures, allows assessment of microvascular density.[@R11] Neoplastic tissue is characterised by increased angiogenesis making adenomas appear darker using NBI.[@R12] The learning curve to accurately assess microvascularity appears to be short,[@R13] making it an attractive and practical option for optical diagnosis.

A large meta-analysis of 56 studies using NBI for optical diagnosis found overall sensitivity to be 91.0% (95% CI 88.6--93.0%), specificity 85.6% (95% CI 81.3--89.0%) and negative predictive value of 82.5% (95% CI 75.4--87.9%).[@R14] Another systematic review and meta-analysis of optical diagnosis for diminutive polyps suggested that accuracy was higher in academic centres and when performed by experienced endoscopists; however, only 3 of 20 NBI studies were undertaken in non-academic settings.[@R15]

Detect Inspect Characterise Resect and Discard (DISCARD) 2 was designed to determine whether clinical management based on NBI-assisted optical diagnosis is accurate in routine clinical practice outside academic centres.

Methods {#s3}
=======

Study design {#s3a}
------------

A UK multicentre, prospective, blinded study comparing surveillance intervals determined by NBI-assisted optical diagnosis and histological assessment in patients referred for colonoscopy.

Hypotheses {#s3b}
----------

NBI-assisted optical diagnosis correctly characterises small colonic polyps as adenomas or hyperplastic, allowing assignment of surveillance intervals with 95% sensitivity compared with histological assessment.

Patients {#s3c}
--------

Adult patients referred for non-emergency colonoscopy (symptomatic referrals and Faecal Occult Blood positive (FOBT) BCSP referrals) between July 2012 and February 2014 were invited to participate and written informed consent obtained. All patients entered Phase 1 of the study, undergoing colonoscopy following standard clinical practice. Patients found to have one or more polyps \<10 mm in size entered Phase 2 of the study. Patients with known IBD (UC or Crohn\'s disease), polyposis syndromes, pregnancy or lack of capacity to give informed consent were excluded.

Setting {#s3d}
-------

Six NHS hospitals in the North of England participated, with a maximum of five recruiting colonoscopists per site. The UK NHS BCSP offers colonoscopy to patients between 60 and 74 years of age with evidence of faecal occult blood, with colonoscopy performed by accredited screening colonoscopists. BCSP colonoscopists may represent a particularly specialised population of endoscopists: to provide generalisable results a maximum of two BCSP colonoscopists were allowed per site.

Training {#s3e}
--------

Colonoscopists underwent training and assessment on the use of NBI in polyp characterisation using a previously validated NBI training module, including the use of the NICE classification[@R16] ([table 1](#GUTJNL2015310584TB1){ref-type="table"}). Colonoscopists had to achieve 90% accuracy for optical diagnosis in the post-training test, with two attempts allowed.[@R12] All procedures were performed using Olympus equipment (Olympus Lucera or Elite processors and 240 or 260 series endoscopes).

###### 

NICE classification

                          Polyp classification using NBI                                                
  ----------------------- ----------------------------------------------------------------------------- --------------------------------------------------------------------------------
  Colour                  \(S\) Same or lighter than the background mucosa                              \(B\) Browner relative to background mucosa
  Vessels                 \(N\) None or isolated lacy vessels                                           \(T\) Thick brown vessels surrounding white structures\*
  Surface pattern         \(D\) Dark or white spots of uniform size or homogeneous absence of pattern   \(O\) Oval, tubular or branched white structures\* surrounded by brown vessels
  Most likely pathology   Hyperplastic                                                                  Adenoma

\*These structures may represent the pits and the epithelium of the crypt opening.

NBI, narrow band imaging; NICE, NBI International Colorectal Endoscopic.

NBI-assisted optical assessment {#s3f}
-------------------------------

During colonoscopy, polyps \<10 mm were evaluated with both white light and NBI. Polyp site, size (measured using an instrument of known size), morphology (Paris Classification)[@R17] and resection method were recorded. Using NBI and NICE classification ([table 1](#GUTJNL2015310584TB1){ref-type="table"}), colonoscopists documented polyp colour, microvessel type and surface pattern, and classified each as adenoma, hyperplastic, cancer or other. Colonoscopists also recorded their diagnostic confidence as high or low. High confidence indicated hypothetically that the colonoscopist would have discarded the polyp without histological assessment, while low confidence indicated sending the polyp for histology. Confidence was considered during polyp level analysis only. Where all polyps identified in a patient were \<10 mm, a surveillance interval (using the British Society for Gastroenterology (BSG) guidelines) based on optical diagnosis was assigned and recorded.[@R18] All polyps were resected by snare polypectomy or by excision biopsy removal and sent for histological assessment. However, if multiple rectal hyperplastic polyps were found, endoscopists were not required to remove all and removal or sampling was done for the first five only. Colonoscopists were given feedback on their optical diagnosis accuracy after every 30 polyps assessed and were informed how well their optical diagnosis correlated with histopathology at per polyp level. No additional training was given during the study period. Endoscopists were not required to differentiate sessile serrated polyps (SSPs).

Histology {#s3g}
---------

Histological assessment using standard H&E staining was performed. Histopathologists classified specimens according to WHO guidelines, blinded to endoscopic images and assessments. A subset from each centre was reviewed by an external specialist GI pathologist. Histological results were returned to lead investigators who, blinded to colonoscopic findings, assigned surveillance intervals per patient providing the reference standard for surveillance. All retrieved polyps \<10 mm were characterised by NBI-assisted optical diagnosis and histology, with histological findings providing the reference standard for assessing optical diagnosis accuracy. All polyps \<10 mm were included in polyp-level assessment whether patients had larger polyps or not.

Outcome measures {#s3h}
----------------

Patient-level test sensitivity was assessed at two thresholds comparing optical diagnosis with the histology reference standard: Presence of an adenoma (including high-risk, intermediate-risk and low-risk findings).Need for surveillance (where some low-risk patients are judged not to require surveillance).

Additionally, three further definitions of test accuracy were assessed: Exact surveillance interval (precise agreement of surveillance interval by optical diagnosis and histology).Conservative matching (correctly identifying or overspecifying need for surveillance)Error rate (false-positive or false-negative diagnosis of adenoma)

In addition to patient-level analyses, factors influencing the accuracy of diagnosis were explored at the polyp level, including patient, organisational, colonoscopist and polyp variables.

Adverse events {#s3i}
--------------

Although there are no known complications of NBI-optical diagnosis, patients were monitored for procedure-related side effects and complications. Adverse events were recorded for 30 days post-procedure in phase II patients.

Sample size {#s3j}
-----------

The study was designed to estimate the test sensitivity of 95% (with 95% CI ±2.5%), based on 290 patients with at least one adenoma (\<10 mm) but only small or diminutive polyps requiring determination of a surveillance interval. Using data from DISCARD and audit,[@R19] an initial phase I sample size of 2500 was estimated based on 20% of patients having only small or diminutive polyps (500); 70% of small polyps anticipated to be adenomas (350) and up to 15% of patients having incomplete histology.[@R20] An interim review indicated that significantly more than 20% of patients had polyps; therefore, the sample size was revised to 1400 phase I patients. Exceeding target recruitment with 1700 patients ensured eligibility criteria for the primary outcome were achieved.

Statistical analyses {#s3k}
--------------------

Test performance was estimated using proportions with CIs (Clopper--Pearson) using STATA IC V.13.1 StataCorp. Exploration of variables at polyp level was performed using xtlogit, where proportions were estimated from models using reported ORs. Modelling provided a hierarchical structure of polyp within patient; population average estimates were used (to prevent overweighting by patients with more numerous polyps) and reported using robust SEs.

Ethical approval {#s3l}
----------------

The study was given a favourable ethical opinion by UK National Research Ethics Committee North East-Newcastle and North Tyneside. Approval was gained from the NHS BCSP Research Committee. A study steering committee provided study oversight. The study was registered with clinicaltrials.gov (NCT01603927). Study reporting followed the STARD statement (<http://www.stard-statement.org>).

Results {#s4}
=======

Patients {#s4a}
--------

Between July 2012 and February 2014, 1688 patients referred for colonoscopy were recruited into phase I across the six participating hospitals: 722 patients (42.8%) had small or diminutive polyps with 567 (78.5%) having only polyps \<10 mm ([figure 1](#GUTJNL2015310584F1){ref-type="fig"}). Mean patient age was 64.3 years (IQR 55.0 to 70.2) and 53.1% were male. Patients were colonoscoped using high definition (HD, 22%) or standard definition (SD, 78%) imaging. [Table 2](#GUTJNL2015310584TB2){ref-type="table"} reports factors associated with higher polyp detection levels at the patient level. The only comorbidity significantly more common in patients with polyps was diabetes mellitus (20.3% vs 10.4%, p\<0.001).

###### 

Screened cohort characteristics

                                      Patients with no polyps   Patients with small polyps   Patients with other findings   Total patients                                           
  ----------------------------------- ------------------------- ---------------------------- ------------------------------ ---------------- ------ ------------ ------ ------------ ---------
  Polyps                                                                                                                                                                             
   No polyps                          883                       100.0                        0                              0.0              0      0.0          883    52.3         \<0.001
   Only small polyps (\<10 mm)        0                         0.0                          567                            100.0            0      0.0          567    33.6         
   Small and large polyps             0                         0.0                          0                              0.0              150    63.0         150    8.9          
   Only large polyps                  0                         0.0                          0                              0.0              58     24.4         58     3.4          
   Polyps and other findings          0                         0.0                          0                              0.0              16     6.7          16     0.9          
   No polyps, cancer suspected        0                         0.0                          0                              0.0              14     5.9          14     0.8          
  Incomplete colonoscopy              54                        6.1                          1                              0.2              9      3.8          64     3.8          \<0.001
   Discomfort-tortuosity related      32                        59.3                         0                              0.0              7      77.8         39     60.9         0.011
   Preparation-related                21                        38.9                         0                              0.0              1      11.1         22     34.4         
   Other                              1                         1.9                          1                              100.0            1      11.1         3      4.7          
  Site                                                                                                                                                                               
   County Durham and Darlington       260                       29.4                         164                            28.9             61     25.6         485    28.7         \<0.001
   North Cumbria                      38                        4.3                          28                             4.9              9      3.8          75     4.4          
   North Tees and Hartlepool          166                       18.8                         156                            27.5             88     37.0         410    24.3         
   Northumbria                        70                        7.9                          37                             6.5              24     10.1         131    7.8          
   South Tees                         193                       21.9                         65                             11.5             20     8.4          278    16.5         
   South Tyneside                     156                       17.7                         117                            20.6             36     15.1         309    18.3         
  Age (years); median, IQR            62.2                      49.8--68.3                   65.9                           60.0--70.4       66.7   62.3--72.4   64.3   55.0--70.2   \<0.001
  Gender                                                                                                                                                                             
   Female                             488                       55.3                         218                            38.4             86     36.1         792    46.9         \<0.001
   Male                               394                       44.7                         349                            61.6             152    63.9         895    53.1         
  Ethnicity                                                                                                                                                                          
   White---British                    866                       99.3                         560                            98.8             235    99.6         1661   99.2         0.218
   Asian or Asian British             5                         0.6                          2                              0.4              0      0.0          7      0.4          
   Black or Black British             0                         0.0                          1                              0.2              0      0.0          1      0.1          
   Chinese or other ethnic groups     1                         0.1                          1                              0.2              1      0.4          3      0.2          
   White---other                      0                         0.0                          3                              0.5              0      0.0          3      0.2          
  Smoking                                                                                                                                                                            
   Current smoker                     142                       16.3                         122                            21.5             40     16.9         304    18.2         \<0.001
   Previous smoker                    321                       36.9                         250                            44.1             113    47.7         684    40.9         
   Never smoked                       407                       46.8                         195                            34.4             84     35.4         686    41.0         
  Alcohol use                         522                       60.1                         365                            64.5             166    69.7         1053   63.0         0.016
   Units/week (users); median, IQR    9.0                       4.0--16.0                    14.0                           6.0--23.5        14.0   6.0--27.0    11.0   5.0--20.0    \<0.001
  Taking any regular medication       720                       81.5                         499                            88.0             198    83.5         1417   84.0         0.004
   Taking an NSAID                    81                        11.2                         38                             7.6              11     5.5          130    9.1          0.018
   Taking a statin                    245                       33.8                         260                            52.1             114    56.7         619    43.4         \<0.001
   Taking aspirin                     138                       19.1                         122                            24.4             50     25.0         310    21.8         0.040
  Primary reason for colonoscopy                                                                                                                                                     
   BCSP                               162                       18.3                         190                            33.5             124    52.1         476    28.2         \<0.001
   Change in bowel habit              276                       31.3                         132                            23.3             37     15.5         445    26.4         \<0.001
   Surveillance procedure             122                       13.8                         137                            24.2             34     14.3         293    17.4         \<0.001
   Per-rectal bleeding                130                       14.7                         59                             10.4             28     11.8         217    12.9         0.050
   Iron-deficiency anaemia            122                       13.8                         60                             10.6             13     5.5          195    11.6         0.001
   Other                              122                       13.8                         19                             3.4              22     9.2          163    9.7          \<0.001
   Abdominal pain                     93                        10.5                         32                             5.6              8      3.4          133    7.9          \<0.001
   Weight loss                        34                        3.9                          23                             4.1              5      2.1          62     3.7          0.389
   Family history                     30                        3.4                          25                             4.4              5      2.1          60     3.6          0.274
   Abnormal imaging                   9                         1.0                          2                              0.4              2      0.8          13     0.8          0.396
  Previous colonoscopy, within 10y    336                       38.1                         272                            48.0             79     33.3         687    40.7         \<0.001
  Previous colorectal cancer (CRC)    32                        3.6                          16                             2.8              3      1.3          51     3.0          0.161
  Previous CRC (years); median, IQR   5.5                       3.9--6.8                     4.8                            1.6--10.2        10.7   4.8--63.8    5.5    3.3--9.6     0.441
  Family history of CRC†              181                       20.5                         120                            21.2             40     16.8         341    20.2         0.352

\*Three-way Fisher's exact test for counts, three-way Kruskal--Wallis test for continuous measures.

†A: Two or more first-degree relatives or one first-degree relative \<45 years old; B: one first-degree relative \>45 years old; C: one or more second-degree or third-degree relative(s); D: none. BCSP, Bowel Cancer Screening Programme; NSAID, non-steroidal anti-inflammatory drug.

![Patient flowchart.](gutjnl-2015-310584f01){#GUTJNL2015310584F1}

Patient-level analysis {#s4b}
----------------------

From the phase I cohort, 722 patients (assessed by 28 colonoscopists) had at least one polyp \<10 mm and entered phase II. Of these, 567 had only small or diminutive polyps permitting patient-level analysis for surveillance interval. A surveillance interval determined by optical diagnosis was unavailable for 3.7% (incomplete data), and surveillance interval determined by histology was unavailable for 11.1% (non-retrieval of polyps or incomplete histology assessment). Comparison of surveillance interval was possible in 499 patients. Of these 499 patients, 452 patients (90.6%) had only diminutive polyps.

Using the threshold of the presence of one or more adenomas (including all high-risk, intermediate-risk and low-risk patients), test sensitivity of optical diagnosis was 83.4% (95% CI 79.6% to 86.9%) ([tables 3](#GUTJNL2015310584TB3){ref-type="table"} and [4](#GUTJNL2015310584TB4){ref-type="table"}). Test sensitivity (correctly identifying need for surveillance vs no surveillance) was 73.0% (95% CI 66.5% to 79.9%). Both measures were considerably lower than the 95% requirement (p\<0.001) set by the study team. When considering exact or conservative matching, test accuracy was 67.9% (64.1% to 71.9%) and 87.6% (84.6% to 90.4%). In post hoc analyses, when considering only diminutive polyps (\<6 mm) test sensitivity of optical diagnosis for detecting adenoma was 83.7% (95% CI 79.5% to 87.4%) and for surveillance was 74.2% (95% CI 66.8% to 80.8%).

###### 

Test performance: need for patient surveillance

                                 Histology interval (reference standard)                                    
  ------------------------------ ----------------------------------------- ---- ---- ---------- ----------- -----------
  NBI colonoscopy interval                                                                                  
   High risk: 1 year             \(a\) 9                                   4    0    (b′) 3     \(b\) 2     18
   Intermediate risk: 3 years    3                                         30   12   10         2           57
   Low risk: 5 years             2                                         13   46   52         13          126
   Low risk: no surveillance     (c′) 0                                    4    9    (d′) 100   19          132
   No adenoma: no surveillance   \(c\) 0                                   4    27   28         \(d\) 107   166
  Total                          14                                        55   94   193        143         \(N\) 499

*Adenoma* *present (solid line partitions)*

Test sensitivity=sum of cells in box (a)/sum of cells in boxes (a)+(c)=297/356=83.4%.

Test specificity=sum of cells in box (d)/sum of cells in boxes (d)+(b)=107/143=74.8%.

Error rate=(b+c)/N=95/499=19.0%.

Surveillance required (dashed line partitions)

Test sensitivity=sum of cells in box (a)/sum of cells in boxes (a)+(c′)=119/163=73.0%.

Test specificity=sum of cells in box (d′)/sum of cells in boxes (d′)+(b′)=254/336=75.6%.

Exact matching=sum of cells with matching surveillance interval / N=339/499=67.9%.

Conservative matching=sum of cells with matching or over surveillance/N=437/499=87.6%.

Error rate=(b′+c′)/N=126/499=25.2%.

NBI, narrow band imaging.

###### 

Test performance: summary findings

  NBI colonoscopy vs histology (reference)   Estimate (%)   95% CI
  ------------------------------------------ -------------- ----------------
  Adenoma (yes/no)\*                                        
   Sensitivity                               83.4           79.6% to 86.9%
   Specificity                               74.8           67.6% to 81.1%
   PPV                                       89.2           85.9% to 92.4%
   NPV                                       64.5           57.3% to 71.8%
  Surveillance (yes/no)\*                                   
   Sensitivity                               73.0           66.5% to 79.9%
   Specificity                               75.6           70.9% to 80.1%
   PPV                                       59.2           52.3% to 66.0%
   NPV                                       85.2           81.0% to 89.1%
  Exact match                                67.9           64.1% to 71.9%
  Conservative match                         87.6           84.6% to 90.4%

\*For explanation see [table 3](#GUTJNL2015310584TB3){ref-type="table"}.

NBI, narrow band imaging; NPV, negative predictive value; PPV, positive predictive value.

Polyp-level analysis {#s4c}
--------------------

The accuracy of NBI-assisted optical diagnosis was explored using polyp-level data comparing optical and histological diagnoses (adenoma vs non-adenoma). In total, 722 patients provided data on 1620 retrieved polyps, with individual patients providing between 1 and 27 polyps (mean 2.2). Of 1620 polyps retrieved, 1580 were characterised by optical diagnosis and 1540 by histology ([table 5](#GUTJNL2015310584TB5){ref-type="table"}). A description of polyp characteristics at the polyp level determined by optical diagnosis is shown in [table 6](#GUTJNL2015310584TB6){ref-type="table"}. Of these polyps, 73.7% were diminutive and 26.3% were small. Of 1014 adenomas identified by histology, the grade of dysplasia was 1 (0.1%) cancer, 3 (0.3%) high-grade dysplasia, 1005 (99.1%) low-grade dysplasia and 5 (0.5%) unreported dysplasia grade. The cancerous polyp was a 5 mm *Is* lesion found in the sigmoid colon and removed by cold snare polypectomy; the optical diagnosis was given with high confidence as adenoma. A villous component was found in 49 (4.8%) adenomas and 964 (95%) were non-villous (status not recorded in 1). Three polyps were histologically reported as SSPs.

###### 

Polyps: optical and histological determination

                    Histology diagnosis (reference standard)                     
  ----------------- ------------------------------------------ ------ ----- ---- ------
  NBI colonoscopy                                                                
   Hyperplastic     305                                        210    75    29   619
   Adenoma          82                                         772    45    40   939
   Other            7                                          8      6     1    22
   Not possible     6                                          24     0     10   40
  Total             400                                        1014   126   80   1620

NBI, narrow band imaging.

###### 

Characterisation of polyps retrieved, by histological determination

                                    Adenoma\*   Hyperplastic\*   Other/not determined\*   Total                       
  --------------------------------- ----------- ---------------- ------------------------ ------- ----- ------ ------ ------
  Polyp size                                                                                                          
   Diminutive (≤5 mm)               706         69.6             315                      78.8    173   84.0   1194   73.7
  Polyp site                                                                                                          
   Ascending colon                  188         18.5             19                       4.8     24    11.7   231    14.3
   Caecum                           119         11.7             18                       4.5     34    16.5   171    10.6
   Descending colon                 99          9.8              22                       5.5     21    10.2   142    8.8
   Distal transverse colon          97          9.6              20                       5.0     17    8.3    134    8.3
   Hepatic flexure                  73          7.2              19                       4.8     12    5.8    104    6.4
   Proximal transverse colon        71          7.0              15                       3.8     6     2.9    92     5.7
   Rectum                           94          9.3              146                      36.5    38    18.4   278    17.2
   Sigmoid                          204         20.1             130                      32.5    41    19.9   375    23.1
   Sigmoid descending               8           0.8              4                        1.0     2     1.0    14     0.9
   Splenic flexure                  61          6.0              5                        1.3     8     3.9    74     4.6
   Not recorded                     0           0.0              2                        0.5     3     1.5    5      0.3
  Polyp shape                                                                                                         
   Ip                               40          3.9              9                        2.3     4     1.9    53     3.3
   Ips                              117         11.5             27                       6.8     12    5.8    156    9.6
   Is                               478         47.1             208                      52.0    101   49.0   787    48.6
   IIa                              349         34.4             149                      37.3    83    40.3   581    35.9
   IIa/c                            2           0.2              0                        0.0     0     0.0    2      0.1
   IIb                              20          2.0              3                        0.8     5     2.4    28     1.7
   Not recorded                     8           0.8              4                        1.0     1     0.5    13     0.8
  Polyp resection                                                                                                     
   Cold biopsy                      171         16.9             168                      42.0    69    33.5   408    25.2
   Cold snare                       540         53.3             146                      36.5    89    43.2   775    47.8
   Endoscopic mucosal resection     44          4.3              13                       3.3     5     2.4    62     3.8
   Hot biopsy                       22          2.2              15                       3.8     1     0.5    38     2.3
   Hot snare                        232         22.9             58                       14.5    25    12.1   315    19.4
   Not recorded                     5           0.5              0                        0.0     17    8.2    22     1.4
  Confidence in optical diagnosis                                                                                     
   High confidence                  769         75.8             340                      85.0    157   76.2   1266   78.1
  NICE classification                                                                                                 
   Vessels: T                       661         65.2             67                       16.8    72    35.0   882    54.4
   Surface pattern: O               696         68.6             85                       21.3    76    36.9   800    49.4
   Colour: B                        726         71.6             82                       20.5    74    35.9   857    52.9
    None of the above               202         20.4             285                      72.3    101   51.8   588    37.2
    One of the above                92          9.3              40                       10.2    23    11.8   155    9.8
    Two of the above                101         10.2             13                       3.3     14    7.2    128    8.1
    Three of the above              595         60.1             56                       14.2    57    29.2   708    44.8

\*Data shown give proportions within groups and are unadjusted for hierarchy at the patient level.

NBI, narrow band imaging; NICE, NBI International Colorectal Endoscopic.

Determinants of test accuracy were explored on the subset of polyps graded as adenoma or hyperplastic by NBI and histology (1369/1620, 85% of cases, [table 5](#GUTJNL2015310584TB5){ref-type="table"}). In an unadjusted hierarchical model, NBI provided test sensitivity of 76.1% ([table 7](#GUTJNL2015310584TB7){ref-type="table"}, model (1)) similar to the patient-level analysis. A number of variables fitted this base model in simple adjusted regression analyses; however, only the presence of NICE polyp characteristics (p\<0.001) and polyp size (p\<0.05) fitted a fully adjusted multivariable model ([table 7](#GUTJNL2015310584TB7){ref-type="table"}).

###### 

Hierarchical regression modelling of adenoma detection

  ---------------------------------------------------------------- --------------------- -------------------
  \(1\) Unadjusted model                                                                 
   Sensitivity                                                     76.1%                 (72.8% to 79.1%)
   Specificity                                                     77.5%                 (71.0% to 82.8%)
                                                                   **Sensitivity (%)**   **(95% CI)**
  \(2\) Model adjusted by polyp characteristics and combinations                         
   None                                                            6.5                   (3.6% to 11.2%)
   T                                                               60.0                  (31.5% to 83.0%
   O                                                               68.0                  (44.5% to 85.0%)
   B                                                               56.8                  (33.2% to 77.7%)
   OB                                                              94.9                  (80.8% to 98.8%)
   TO                                                              96.7                  (76.0% to 99.6%)
   TB                                                              97.3                  (80.3% to 99.7%)
   TOB                                                             99.9                  (97.8% to 100.0%)
  \(3\) Model adjusted by number of polyp characteristics\*                              
   None                                                            6.5                   (3.6% to 11.4%)
   1 of TOB                                                        62.3                  (42.7% to 78.6%)
   2 of TOB                                                        96.3                  (88.5% to 98.9%)
   3 of TOB                                                        99.9                  (97.9% to 100.0%)
  ---------------------------------------------------------------- --------------------- -------------------

Hierarchical regression models of polyps nested within patients (see Methods section).

Polyp categories:

None denotes a polyp without T, O or B observed.

T=Thick brown vessels surrounding white structures.

O=Oval, tubular or branched white structures surrounded by brown vessels.

B=Browner relative to background.

\*Model 3 was rerun with two or three polyp characteristics combined giving a test sensitivity of 99.4% (95% CI 98.2% to 99.8%) when two or more characteristics were present.

NICE characteristics {#s4d}
--------------------

When considering NICE polyp characteristics test sensitivity at polyp level was 99.9% (95% CI 97.8% to 100.0%), where all three characteristics suggestive of an adenoma were positively identified (T=Thick brown vessels surrounding white structures, B=Browner relative to background, O=Oval, tubular or branched white structures surrounded by brown vessels). If ≥2 characteristics were identified, then the sensitivity was 99.4% (95% CI 98.2% to 99.8%). Of 1369 polyps included, 727 (53.1%) were graded T; 779 (56.9%) graded O and 799 (58.4%) graded B. In combination, 651 (47.6%), 113 (8.3%), 126 (9.2%) and 479 (35.0%) had three, two, one and no characteristics, respectively.

Confidence, expertise, image resolution and colonic site {#s4e}
--------------------------------------------------------

In univariable analyses, test sensitivity was significantly greater with BCSP expertise (yes: 83.0% vs no: 64.1%, p\<0.001). Confidence in polyp diagnosis (yes: 77.1% vs no: 72.0%, p=0.19) was not significant. However, neither expertise nor confidence were independently important influence in the final adjusted model. Colonoscopists reported high confidence assessing 78.1% of polyps ([table 6](#GUTJNL2015310584TB6){ref-type="table"}). Further exploration of confidence in patients with two or more NICE signs showed no difference in polyp diagnoses with high and low confidence. Image resolution did not affect test sensitivity: univariable analyses test sensitivity for HD: 77.3% vs SD: 75.8% (p=0.65). Test sensitivity was not affected by the site of polyp in the colon.

External review of histopathology {#s4f}
---------------------------------

Repeat histology was conducted on 193 polyps of which 189 were assessable (12% total polyps). The disagreement rate was 3.4% or 11.1% depending on narrow or inclusive definition of matching. The narrow definition compared only adenoma and hyperplasia matching; the inclusive definition included other categories used either by original or review histology. External review showed that histopathology did not provide a perfect reference standard.

Adverse events {#s4g}
--------------

During phase II, 55 adverse events were reported. Four were serious but only one (mild bleeding post polypectomy) was colonoscopy related. No perforations occurred among patients recruited to this trial.

Discussion {#s5}
==========

This largest multicentre prospective community study to date, evaluating the use of NBI-assisted optical diagnosis in routine clinical practice demonstrates that optical diagnosis in the hands of non-experts is not currently accurate enough to replace histology in determining surveillance for patients with colonic polyps. Regardless of the threshold employed, test sensitivity was significantly below required levels and below those reported in academic centres, which report concordance between optical and histology-based surveillance intervals of \>90%.[@R19] [@R21]

The Preservation and Incorporation of Valuable Endoscopic Innovations (PIVI) statement issued by the American Society of GI Endoscopy has issued advice on acceptable performance thresholds for real-time endoscopic assessment of diminutive polyps required before optical diagnosis should be recommended for routine clinical practice.[@R22] The PIVI statement advises that optical diagnosis can be used for diminutive (1--5 mm) and histological diagnosis for small (6--9 mm) polyps and those summated results used to determine surveillance. In expert hands, optical diagnosis of small polyps using white light and NBI has been shown to be comparable to histology.[@R19] [@R21] A large meta-analysis showed per polyp sensitivity of 91% and specificity of 83%,[@R23] but results from general settings have not replicated those values, with sensitivities ranging from 75% to 94% and specificity 65% to 76%.[@R24] The present study used optical diagnosis for both small and diminutive polyps to determine surveillance interval but as 91% of patients had only diminutive polyps, the inclusion of small polyps did not significantly affect determination of surveillance interval. Accuracy of adenoma characterisation at the polyp level in the present study was 83%. The NHS BCSP provides a high standard of practice with colonoscopists accredited and regularly quality assured. In this study, performance was better for screening colonoscopists in univariable analysis but not in adjusted models. A meta-analysis reported that pooled negative predictive value was higher when optical diagnosis was made with high confidence as opposed to when no information on confidence was given (93% vs 88%) as well as higher agreement in surveillance intervals for high confidence (91% vs 79%).[@R15] Non-experts in community practice made 49% of diagnoses with high confidence before training and 72% after training in optical diagnosis.[@R27] Some studies assessing experienced endoscopists have reported high confidence optical diagnosis in over 85% of cases.[@R28] The current study found that high confidence predictions were made in 78.1% of polyps but confidence did not influence test accuracy.

A Discard policy relies on accurate estimation of polyp size. It is recommended that polyp size is estimated against an instrument of known size such as an open biopsy forceps. Even using such an approach, estimation of size maybe inaccurate.[@R29] Tools such as the endoscopic lesion measurement system have been developed. This consists of a graduated measurement device that can be passed down the biopsy channel and placed alongside the lesion to aid measurement and has been shown to be superior to clinician estimation.[@R30] Such systems warrant further evaluation as size is a fundamental part of a potential Discard policy.

The rate of SSPs reported in this study is low when compared with the reported prevalence of 0.3--0.5%.[@R31] One study has suggested that the use of NBI might improve the detection of SSPs although the increase detected did not reach statistical significance.[@R32] In the present study, colonoscopists were asked to classify polyps as adenomas, hyperplastic, cancer or other and were not expected to specifically diagnose sessile serrated adenomas or polyps. Recent work has highlighted typical endoscopic features that may be used to distinguish SSPs from hyperplastic polyps.[@R33] These features, together with the NICE classification, have been combined to develop the Workgroup serrAted polypS and Polyposis (WASP) classification. Using WASP, it has been shown that, following training, an accuracy of optical diagnosis for SSA/Ps 0.87 (95% CI 0.80 to 0.95) could be achieved when diagnoses were made with high confidence. Six months after training, accuracy was 0.84 (95% CI 0.81 to 0.88) when made with high confidence. The use of the WASP classification could be incorporated into future training modules in optical diagnosis.

Accurate adenoma identification by NBI was heavily dependent on identification of the three NICE polyp characteristics. If two or more features were present (55.9% of polyps), the sensitivity for correctly identifying adenomas exceeded 99%. The discrepancy between this finding and overall test sensitivity, combined with a high percentage of high confidence diagnoses, raises the possibility that endoscopists were relying on factors other than NICE criteria to make the optical diagnosis. Where NICE features were identified, accuracy was high but the present study cannot determine whether NICE features were not consistently present or features were incorrectly interpreted. Previous studies suggest a short learning curve for optical diagnosis[@R16] [@R34]; however, training using still images and videos may not translate into accuracy in vivo. The current study is consistent with a previous study where 12/13 community-based gastroenterologists identified adenomas with \>90% accuracy following training but only 3/12 managed this in vivo.[@R25] This was a pragmatic study designed to examine whether NBI worked in clinical practice. While double reporting of histology was undertaken to assess reliability and training and feedback on NBI were given, it did not incorporate more formal testing of reliability and did not aim to test explanatory factors related to how NBI did or did not work.

As this was a pragmatic study generalisable to routine clinical practice, the protocol did not mandate use of HD or SD colonoscopes. Consequently, only 22% of patients (20% of polyps) were assessed with HD, although this did not significantly alter test sensitivity. Most studies that have achieved results comparable to reference standard have used HD systems[@R15]; however, a meta-analysis of all NBI studies reported that HD significantly decreased the performance of NBI, a possible explanation was that some of these studies also used magnification, making data more heterogeneous.[@R14]

Optical diagnosis remains an attractive idea because of the potential for reducing costs and streamlining care. This study demonstrates that correctly characterising diminutive polyps using optical diagnosis represents a major challenge. One method for improving accuracy could be the use of computer-aided diagnosis, which has been shown to be feasible in a pilot study.[@R35] Should the accuracy of optical diagnosis be improved, validated accreditation programmes and on-going quality assurance would be required in order for it to be incorporated into routine practice.

Conclusions {#s6}
===========

Previous research, predominantly from single sites and academic groups, suggests that NBI-assisted optical diagnosis has acceptable accuracy to determine surveillance without histology. These findings were not replicated in this large, multicentre study of NBI use in routine practice, either at the polyp or patient level. The marked variation of accuracy according to the polyp characteristics detected is notable: either a proportion of polyps present without NBI detectable signs or colonoscopists vary in their ability to evaluate them. The first explanation would require imaging advances; the second further research into training and accreditation. NBI-assisted optical diagnosis of small polyps during colonoscopy cannot currently be recommended for routine use outside of specialist centres.
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